Loading stock data…
VNDA
$6.43+0.01 (+0.16%)
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vanda Pharmaceuticals Inc. in the Healthcare sector is trading at $6.43. Wall Street consensus targets $14.90 (5 analysts), implying a +131.7% move over the next 12 months. The stock is currently 35% below its 52-week high of $9.94, remaining 4.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +131.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$6.43
Potential Downside
0%
Whystock Fair Value$6.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$395.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.46%
Volume
Today's trading volume
1.08M
Recent News
Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks […]
Vanda Pharmaceuticals Q1 Earnings Call Highlights
Vanda Pharmaceuticals (NASDAQ:VNDA) reported first-quarter 2026 revenue of $51.7 million, a 3% increase from $50.0 million in the prior-year period, as growth in Fanapt was partially offset by continued declines in HETLIOZ amid generic competition. Management also highlighted the U.S. commercial lau
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby summary of Vanda Pharmaceuticals Inc.'s Q1 2026 earnings call
Vanda (VNDA) Q1 2026 Earnings Call Transcript
Kevin Moran: Thank you, Jordan. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals Inc.’s first quarter 2026 performance. Joining me on today’s call is Mihael H. Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board.
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -54.72% and -9.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?